- Home
- KDK vs VCEL Comparison
KDK vs VCEL Comparison
Compare KDK & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KDK | VCEL |
|---|---|---|
| Founded | 2018 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | KDK | VCEL |
|---|---|---|
| Price | $8.51 | $32.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $15.38 | ★ $58.50 |
| AVG Volume (30 Days) | 342.6K | ★ 446.2K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | $250.51 | $19.09 |
| Revenue Next Year | $435.96 | $17.96 |
| P/E Ratio | ★ N/A | $100.34 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $5.43 | $29.24 |
| 52 Week High | $11.35 | $48.75 |
Technical Indicators
Market Signals| Indicator | KDK | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 46.78 | 34.04 |
| Support Level | $7.25 | $31.34 |
| Resistance Level | $9.54 | $38.48 |
| Average True Range (ATR) | 0.54 | 1.41 |
| MACD | 0.05 | -0.37 |
| Stochastic Oscillator | 55.06 | 15.85 |
Price Performance
Historical ComparisonAbout KDK Kodiak AI Inc.
Kodiak AI Inc is engaged in the commercial trucking industry and the public sector, based on AI-powered autonomous vehicle technology.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.